Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
You may also be interested in...
The company said its own calculations suggested a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
New Chief Technology Officers named at Seres Therapeutics, ERYTech Pharma and Adicet Bio
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.